Overview: Chromogranin A Immunohistochemistry TestIntroduction: The Chromogranin A Immunohistochemistry Test detects chromogranin A protein to diagnose neuroendocrine tumors, causing hormonal imbalances or pain. Aligned with 2023 NCCN guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected neuroendocrine tumors.
Other Names: Chromogranin A IHC Assay, Neuroendocrine Tumor IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: Chromogranin A testing began in the 1980s with neuroendocrine research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects chromogranin A to diagnose neuroendocrine tumors, guides treatment, and evaluates patients with hormonal imbalances or pain.
Test Parameters: 1. Chromogranin A Protein
Pretest Condition: No fasting required. Collect tissue via biopsy or surgical resection. Report history of hormonal imbalances, pain, or neuroendocrine symptoms.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document hormonal imbalances, pain, flushing, or family history of neuroendocrine tumors. Include current medications, especially somatostatin analogs.
Consent: Written consent required, detailing the tests purpose, tumor implications, and risks of biopsy or surgery.
Procedural Considerations: Uses immunohistochemistry to detect chromogranin A in tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for neuroendocrine tumor diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive chromogranin A staining confirms neuroendocrine tumors, guiding surgery or medical therapy. Negative staining may require further tumor marker testing.
Specialist Consultation: Consult an oncologist or endocrinologist for result interpretation and treatment planning.
Additional Supporting Tests: Synaptophysin IHC, serum chromogranin A, or PET-CT to confirm neuroendocrine tumor diagnosis.
Test Limitations: Not specific to one neuroendocrine tumor; other conditions may express chromogranin A. Clinical correlation is needed.
References: NCCN Neuroendocrine Tumor Guidelines, 2023; American Journal of Surgical Pathology, Klimstra DS, 2022.
